NCT02023099COMPLETEDanonymous

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)

Sponsor

Source record

AbbVie

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

ABT-450/r/ABT-267, Placebo

Indication / condition

AI-normalized

Chronic Hepatitis C Infection

Intervention

Source record

ABT-450/r/ABT-267, Placebo

Related intelligence directories

Indication directory: Chronic Hepatitis C Infection Modality directory: small molecule Target directory: ABT-450/r/ABT-267

Source & freshness

Source record

NCT ID

NCT02023099

Original source

ClinicalTrials.gov

Source last updated

Jun 06, 2018

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02023099

Title

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)

Sponsor

AbbVie

Status

COMPLETED

Phase

PHASE3

Condition raw

Chronic Hepatitis C Infection

Condition normalized

Chronic Hepatitis C Infection

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ABT-450/r/ABT-267, Placebo

Target normalized

ABT-450/r/ABT-267, Placebo

Interventions

ABT-450/r/ABT-267, Placebo

Public preview

Source record

This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects with compensated cirrhosis.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT02023099

Status

COMPLETED

Phase

PHASE3

Sponsor

AbbVie

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 06, 2018

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02023099

Indication

Chronic Hepatitis C Infection

Modality

small molecule

Target

ABT-450/r/ABT-267, Placebo

Intervention

ABT-450/r/ABT-267, Placebo

Source record